Effects of cyclosporine on transplant tolerance: The role of IL-2

American Journal of Transplantation

Volumn 7, Issue 8, 2007, Pages 1907-1916

  Kang, H G ^a   Zhang, D ^a   Degauque, N ^a   Mariat, C ^a   Alexopoulos, S ^a   Zheng, X X ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

IL 2; Immunosuppressive drugs; Regulatory T cells; Tolerance; Transplantation

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOSPORIN A; INTERLEUKIN 2;

ALLOIMMUNITY; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GRAFT SURVIVAL; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; CD40 LIGAND; CELL PROLIFERATION; CYCLOSPORINE; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 34447136750     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01881.x     Document Type: Article

References (55)

1. Quezada SA, Fuller B, Jarvinen LZ et al. Mechanisms of donor-specific transfusion tolerance: Preemptive induction of clonal T-cell exhaustion via indirect presentation. Blood 2003 102 : 1920 1926.
2. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question. J Immunol 2001 166 : 973 981.
3. Fischer, Lindahl K, Wilson DB. Histocompatibility antigen-activated cytotoxic lymphocytes II. Estimates of frequency and specificity of precursors. J Exp Med 1977 145 : 508 522.
4. Teh HS, Harley E, Phillips RA, Miller RG. Quantitative studies on the precursors of cytotoxic lymphocytes I. Characterization of a clonal assay and determination of the size of clonal derived from single precursors. J Immunol 1977 118 : 1049 1056.
5. Schneider TM, Kupiec-Weglinski JW, Towpik E et al. Development of suppressor lymphocytes during acute rejection of rat cardiac allografts and preservation of suppression by anti-IL-2-receptor monoclonal antibody. Transplantation 1986 42 : 191 196.
6. Hall BM, Jelbert ME, Dorsch SE. Suppressor T cells in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Transplantation 1984 37 : 595 600.
7. Cobbold S, Waldmann H. Infectious tolerance. Curr Opin Immunol 1998 10 : 518 524.
8. Sanchez-Fueyo A, Domenig C, Strom TB, Zheng XX. The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression. Transplantation 2002 74 : 898 900.
9. Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10- dependent immunoregulation of alloresponses. J Immunol 2002 168 : 1080 1086.
10. Taylor PA, Lees CJ, Waldmann H, Noelle RJ, Blazar BR. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001 98 : 467 474.
11. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc Natl Acad Sci USA 1993 90 : 2774 2778.
12. Sanchez-Fueyo A, Weber M, Domenig C, Strom TB, Zheng XX. Tracking the immunoregulatory mechanisms active during allograft tolerance. J Immunol 2002 168 : 2274 2281.
13. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002 195 : 1641 1646.
14. Asao H, Okuyama C, Kumaki S et al. Cutting edge: The common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001 167 : 1 5.
15. Shevach EM. Suppressor T cells: Rebirth, function and homeostasis. Curr Biol 2000 10 : R572-575.
16. Domenig C, Sanchez-Fueyo A, Kurtz J et al. Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol. J Immunol 2005 175 : 51 60.
17. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999 5 : 1298 1302.
18. Wells AD, Li XC, Li Y et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999 5 : 1303 1307.
19. Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 1998 161 : 1659 1663.
20. Shi YF, Sahai BM, Green DR. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 1989 339 : 625 626.
21. Trambley J, Lin A, Elwood E et al. FasL is important in costimulation blockade-resistant skin graft rejection. Transplantation 2001 71 : 537 543.
22. Smiley ST, Csizmadia V, Gao W, Turka LA, Hancock WW. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: Implications for tolerance induction. Transplantation 2000 70 : 415 419.
23. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002 196 : 851 857.
24. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004 172 : 6519 6523.
25. Thornton AM, Piccirillo CA, Shevach EM. Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 2004 34 : 366 376.
26. Banz A, Pontoux C, Papiernik M. Modulation of Fas-dependent apoptosis: A dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J Immunol 2002 169 : 750 757.
27. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. Regulatory CD4 T cells: Expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998 10 : 371 378.
28. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta- deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002 17 : 167 178.
29. Zheng XX, Li Y, Li XC et al. Blockade of CD40L/CD40 costimulatory pathway in a DST presensitization model of islet allograft leads to a state of Allo-Ag specific tolerance and permits subsequent engraftment of donor strain islet or heart allografts. Transplant Proc 1999 31 : 627 628.
30. Jarvinen LZ, Blazar BR, Adeyi OA, Strom TB, Noelle RJ. CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance. Transplantation 2003 76 : 1375 1379.
31. Sanchez-Fueyo A, Tian J, Picarella D et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003 4 : 1093 1101.
32. Ringers J, Haanstra KG, Kroczek RA et al. Blockade of CD40-CD154 at the time of donor-specific blood transfusion does not lead to prolonged kidney allograft survival in nonhuman primates. Transplantation 2002 73 : 862 866.
33. Camirand G, Caron NJ, Turgeon NA, Rossini AA, Tremblay JP. Treatment with anti-CD154 antibody and donor-specific transfusion prevents acute rejection of myoblast transplantation. Transplantation 2002 73 : 453 461.
34. Iwakoshi NN, Markees TG, Turgeon N et al. Skin allograft maintenance in a new synchimeric model system of tolerance. J Immunol 2001 167 : 6623 6630.
35. Gordon EJ, Woda BA, Shultz LD, Rossini AA, Greiner DL, Mordes JP. Rat xenograft survival in mice treated with donor-specific transfusion and anti-CD154 antibody is enhanced by elimination of host CD4+ cells. Transplantation 2001 71 : 319 327.
36. Zheng XX, Steele AW, Hancock WW et al. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J Immunol 1999 163 : 4041 4048.
37. Wells AD, Gudmundsdottir H, Turka LA. Following the fate of individual T cells throughout activation and clonal expansion. J Clin Invest 1998 100 : 3173 3183.
38. Parker DC, Greiner DL, Phillips NE et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic amall lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995 92 : 9560.
39. Janeway CAJ, Travers P, Walport M, Shiomchik MJ. Immunology, 6th ed. Galand Science Publishing, NY 2005 : 616.
40. Sho M, Sandner SE, Najafian N et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002 236 : 667 675.
41. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996 381 : 434 438.
42. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 Knockout recipient mice reject islet cell allografts. J Immunol 1995 155 : 489 498.
43. Klebb G, Autenrieth IB, Haber H et al. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin Immunol Immunopathol 1996 81 : 282 286.
44. Almeida AR, Legrand N, Papiernik M, Freitas AA. Homeostasis of peripheral CD4 +T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 2002 169 : 4850 4860.
45. Bensinger SJ, Walsh PT, Zhang J et al. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol 2004 172 : 5287 5296.
46. Zheng XX, Sanchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003 19 : 503 514.
47. Kim YS, Maslinski W, Zheng XX et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J Immunol 1998 160 : 5742 5748.
48. Ferrari-Lacraz S, Zheng XX, Kim YS et al. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J Immunol 2001 167 : 3478 3485.
49. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999 17 : 19 49.
50. Li XC, Demirci G, Ferrari-Lacraz S et al. IL-15 and IL-2: A matter of life and death for T cells in vivo. Nat Med 2001 7 : 114 118.
51. Zheng XX, Sanchez-Fueyo A, Domenig C, Strom TB. The balance of deletion and regulation in allograft tolerance. Immunol Rev 2003 196 : 75 84.
52. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006 311 : 1924 1927.
53. Tran HM, Nickerson PW, Restifo AC et al. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol 1997 159 : 2232 2239.
54. Tan P, Anasetti C, Hansen JA et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993 177 : 165 173.
55. Dallman MJ, Shiho O, Page TH, Wood KJ, Morris PJ. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991 173 : 79 87.